Matricelf is a pioneering biotechnology company developing a platform for autologous matrix and cells implants for a wide range of medical conditions. The company was established in 2019 by Professor Tal Dvir of the Laboratory for Tissue Engineering and Regenerative Medicine from Tel Aviv University. Our patented technology is a product of eight years of research and $12 million in grants.
* Tel Aviv University, Prof Dvir laboratory
Dr. Toker is a seasoned CEO with a proven track record in the biotechnology and healthcare industries. He possesses strong business development skills with prior experience in medical devices, R&D, and Life Sciences. Dr. Toker is a pediatrician and also has a degree in Health Systems Management and MSc in Biotechnology Engineering from Ben Gurion University of the Negev.
Dr Toker served in several executive positions in the private and public healthcare system and served as a director in several biotechnology and medical device companies.
Professor Dvir obtained his Ph.D. in Biotechnology Engineering from Ben Gurion University of the Negev in Israel. His Ph.D. research focused on cardiac tissue engineering and regeneration. Prof. Dvir continued his postdoctoral studies in the laboratory of Professor Robert Langer in the Department of Chemical Engineering at MIT. His postdoctorial research focused on nanotechnological strategies for engineering complex tissues. In 2011, Professor Dvir was recruited by the Department of Biotechnology and the center for Nanotechnology at Tel Aviv University to establish the Laboratory for Tissue Engineering and Regenerative Medicine. In 2013, he joined the newly established Department of Materials Science and Engineering at Tel Aviv University, where he has also served as an Associate Professor in the Department of Biotechnology since 2015.
Alon Sinai brings over 25 years of operational and managerial experience in medical corps of the Israeli Defense Forces. He holds a Master’s degree in Health Systems Management and a Bachelor’s degree in emergency medicine.
Tal holds a MSc. in Materials Engineering and Nanotechnology and a BSc. in Life and Medical Sciences, both from Tel Aviv University.
Tal worked for more than eight years at CollPlant (NASDAQ: CLGN), a medical device company focused on regenerative medicine, as product development engineer, project manager and program manager.
Tal led multidisciplinary activities from early development to regulatory approval including clinical phase of the company’s two commercial products and we are sure that Tal will help us achieve our research and development goals.
Tamar Harel Adar, PhD brings years of experience in Biotechnology, having previously worked for CollPlant biotechnology (NASDAQ: CLGN) and Cellect Biotherapeutics (NASDAQ: APOP). Tamar has completed her Biotechnology Engineering doctoral studies at Ben Gurion University of the Negev.